Teva Moves Shares to Direct NYSE Trading From ADRs
Teva Pharmaceuticals President and CEO Richard Francis explains the rationale behind shifting from American Depositary Receipts to direct New York Stock Exchange listing.
This story has stopped developing; this page is its permanent record. More from that day
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Teva Pharmaceuticals
- Richard Francis
- NYSE